TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04275453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG is a FDA approved radiotracer which each subject will have 3 positron emission tomography/computed tomography (PET/CT) scan performed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Drink
Description: Subjects will undergo FDG PET/CT after 1 dose of ketone drink administration after 12 hours of fasting prior to FDG injection. The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenetic Diet
Description: Subjects needs to be on Ketogenetic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenetic Diet
Description: Subjects needs to be on Ketogenetic diet
Study: NCT03038711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986166
Description: Specified dose on specified days
Study: NCT05382429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OWHTO
Description: OWHTO Surgical procedure For the OWHTO Surgical procedure, only medial split biplanar osteotomy performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CWHTO
Description: CWHTO Surgical procedure For the OWHTO Surgical procedure, only lateral closure osteotomy was performed.
Study: NCT04089501

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool collection
Description: Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy collection
Description: 3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care

Intervention type: DIAGNOSTIC_TEST
Intervention: Biopsy collection
Description: 3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
Study: NCT02660437

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation program
Description: Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation program
Description: Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; \~30min).
Study: NCT02800369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZFN-603 and ZFN-758
Description: Each suppository contain 500 µg of ZFN-603 or ZFN-758
Study: NCT02186158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02362191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternating Current Stimulator
Description: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
Study: NCT02815267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101, 4% minocycline foam
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam applied topically once daily for 12 weeks
Study: NCT03995927

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
Study: NCT01717157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
Study: NCT01648153

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1070806
Description: To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: To compare the efficacy and biomarker changes between placebo and active groups

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK1070806
Description: To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
Study: NCT01717157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
Study: NCT03435146

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3HP plus DTG +2NRTIs
Description: * HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC (Groups 1 and 2) or with TDF/3TC (Groups 3 and 4).~* LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg (Groups 1,2 and 4) Isoniazid at standard of care dosing (Group 3)
Study: NCT01714167

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: intracerebral stem cell transplantation
Description: Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
Study: NCT02847442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/dopa decarboxylase inhibitor
Description: OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
Study: NCT00712647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Carotene and Retinol
Description: Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard \& Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebos, one each/day
Study: NCT04154969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy including Vestibular rehabilitation
Description: vestibular exercise (VOR TX1)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional Physiotherapy
Description: conventional Physiotherapy
Study: NCT04537988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: eCHANGE
Description: eCHANGE is an eHealth intervention aiming to support long-term weight maintenance after initial weight loss
Study: NCT03792490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Fasudil hydrochloride hydrate IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: Fasudil hydrochloride hydrate IV solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
Study: NCT01409005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and UFTE chemotherapy
Description: Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1\~21~Interval: every 4 weeks
Study: NCT01545947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, erlotinib
Description: Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, oral azacitidine
Description: Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223, oral azacitidine
Description: Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy
Study: NCT00929253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone
Description: Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone
Description: Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CRA
Description: Computer-delivered Community Reinforcement Approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Therapist-delivered therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Therapist-delivered therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CM
Description: Contingency management (vouchers) for providing a drug negative urine sample.
Study: NCT01717157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
Description: One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
Study: NCT03013712

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
Study: NCT02632370

Intervention type: DRUG
Intervention: Gliolan®
Description: single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively

Intervention type: PROCEDURE
Intervention: Fluorescence-Guided Surgery
Description: performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
Study: NCT06458777

Intervention type: DIAGNOSTIC_TEST
Intervention: poligraphy
Description: OSA diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: poligraphy
Description: OSA diagnosis
Study: NCT00929253

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CM
Description: Contingency management (vouchers) for providing a drug negative urine sample.
Study: NCT02210325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Study: NCT01915550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin Insulin Mixtard
Study: NCT01400906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 micrograms Fluticasone propionate
Description: 100 micrograms micronized drug blended with lactose in dry powder inhalator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 500 micrograms Fluticasone propionate
Description: 500 micrograms micronized drug blended with lactose in dry powder inhalator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose powder
Description: lactose powder in dry powder device : placebo comparator
Study: NCT01041274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: 40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth daily for 12 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: 16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: 3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
Study: NCT03453697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acute intermittent hypoxia
Description: Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%\~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
Study: NCT00203047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Description: 20mg glatiramer acetate (GA) administered by daily subcutaneous injections
Study: NCT03701152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Negative pressure therapy at sub atmospheric level

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Negative pressure therapy at sub atmospheric level
Study: NCT01681095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol HTK
Description: After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold Blood Cardioplegia
Description: After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
Study: NCT00203047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate
Description: 20mg glatiramer acetate (GA) administered by daily subcutaneous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for prednisone given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1250 mg taken daily
Study: NCT02497495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion cold water
Description: immersion cold water at different temperatures and exposure times
Study: NCT00548743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening and follow up
Description: Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: usual care for identification and management of postpartum depression
Study: NCT04623762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: yoga application
Study: NCT01537692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA Nasal Aerosol
Description: BDP HFA Nasal 80mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA Nasal Aerosol
Description: BDP HFA Nasal 320mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDP HFA Inhalation Aerosol (QVAR)
Description: BDP HFA Oral 320mcg
Study: NCT02036138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y Gastric Bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Medical Therapy
Study: NCT02723227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Coaching
Description: Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to Social Services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Social Services
Study: NCT04487470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flavored filtered cigars
Description: Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unflavored filtered cigars
Description: Flavored and unflavored Cheyenne filtered cigars that are currently available in the marketplace for purchase
Study: NCT02565524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetic and phenotypic profile
Description: Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood